Navigation Links
Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting

r the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the National Cancer Institute (NCI). Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities of associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK's option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct at its expense a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics. Cytokinetics expects to incur approximately $4-7 million of incremental costs in 2007 related to assuming additional clinical development responsibilities under the amendment to the collaboration agreement with GSK.

GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second--or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these studies has been closed. To date, clinical activity for ispinesib has been observed in non-small cell lung cancer and breast cancer, with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. GSK has informed Cytokinetics that final data is expected from the
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...
(Date:11/19/2009)...Nov. 19 BioCryst Pharmac...e pricing of a public offering of 5,000,000 shares... in gross proceeds of $48.75 million. All of the ...n effective shelf registration statement previousl...n. BioCryst has also granted the underwriters a 3...
(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3OPAXIO 28TM 29 Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annu 5050 1Open innovation networks are one key to improved care 58222 1Open innovation networks are one key to improved care 58222 2Open innovation networks are one key to improved care 58222 3Open innovation networks are one key to improved care 58222 4Open innovation networks are one key to improved care 58222 5Fish fend off invading germs with an initial response similar to the one found in people 10082 1Fish fend off invading germs with an initial response similar to the one found in people 10082 2
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ...oday announced that it will present updated result...one-year survival data, during a,poster discussion...Study of,Lung Cancer,s (IASLC) 12th World Conferen... Poster number: PD6-1-1 Title: A phase 2 study o...
... (Nasdaq:,VICL) announced today that results from ...using a plasmid DNA (pDNA) vaccine developed by th...Vical, reinforced previously,reported Phase 1 conc...,vaccine regimen was safe and well-tolerated, and ...in up to 70% of the vaccine recipients. "These re...
Other Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3
(Date:11/22/2009)...-USNewswire/ -- Congressman Chaka Fattah (D-PA) is...s Senate,s vote tonight to proceed to debate on Af...Arlen Specter and Bob Casey deserve the thanks of ...stand-up, critical votes in the Senate tonight adv...h Care Reform legislation to full debate. The Pres...
(Date:11/21/2009).../ -- Milvia Lopez, by her attorney MICHAEL STEWART...n Supreme Court, New York County, bearing Index # ...Lopez underwent a routine transesophageal echocard...s used an HIV infected scope exposing her to HIV. ...fter being discharged from the procedure and arriv...
(Date:11/21/2009)...l credentialing software company IntelliSoft Group...p with Amerinet, Inc., the leading healthcare G.P....sform quality care within the healthcare market. ...9 -- ISG Group, LLC, doing business as IntelliSoft...t Inc., a leading national healthcare group purcha...
(Date:11/21/2009)...l Group merges their practice with that of E. Stev... (PRWEB) November 21, 2009 -- The New H... Gibson, Dr. Dean Cloutier, Dr. John Plachtyna and...g practice with that of esteemed colleague Dr. E. ...nted to retire from dentistry in order to concentr...
(Date:11/20/2009)...ire-USNewswire/ -- The American Academy of Actuar...form legislation released this week to contain str...dual coverage mandate. The actuaries said that an ...verse selection stemming from more restrictive iss..."The individual mandate language should be strengt...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2
...t Listed on Product Labels Due to Weak Regulatory ...ting claims like "gentle" and "pure," dozens of to...d with the cancer-causing chemicals formaldehyde a...abels because contaminants are exempt from labelin...
...March 12 For the past three decades, employers ha...e costs. Now some are pinning their hopes on a rel..., which link high-deductible health insurance plan...ent in Health Care -- 30 Years into the Experiment...
...perts in cancer and nutrition are meeting in Zuric...edge research in one of the most important and fie...k between diet and cancer. , There is growing ev...so have a negative impact on cancer management and...
...- The long tails sported by many male birds in the...and a distinct disadvantage when fleeing predators...keley, biologists shows that they exact only a min...cent, which means the bird has to visit 1 to 3 per...
...ass., March 12 North American application activit... up +1.1% in February, year-over-year, according t...from January to February 2009 was up +12.9%. Year...butable to the Life Index methodology rather than ...
...Partners Offer Consumers Chance to Win Tickets to ...RSIPPANY, N.J., March 12 alli announced today a s...ity to attend a private Wynonna Judd concert in Na...nd,s spokesperson, in an intimate setting while sh...
Other Medicine News:Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 2Health News:Children's Bath Products Contaminated With Formaldehyde, 1,4-Dioxane 3Health News:EBRI Policy Forum: Consumer/Patient Engagement in Health Care - 30 Years On 2Health News:New data on link between cancer and nutrition discussed at European symposium 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:MIB Life Index Reports North American Life Insurance Activity up 1.1% in February 2Health News:MIB Life Index Reports North American Life Insurance Activity up 1.1% in February 3Health News:Wynonna Judd and alli Host Private Concert in Nashville 2
Ocular Three Mirror 10 mm Gonio
Ocular Magna View Gonio
Ocular Koeppe Diagnostic
Mcintyre Cannula
Medicine Products: